ORPHA:213512
Malignant mixed Müllerian tumor of the ovary
Also known as: MMMT of the ovary · Ovarian carcinosarcoma · Ovarian malignant mixed Müllerian tumor · Ovarian malignant mixed epithelial mesenchymal tumor
Publications
966
91.2th percentile
Trials
26
Interventional, condition-specific
Researchers
1,322
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Malignant mixed Müllerian tumor of the ovary is a rare and very aggressive neoplasm presenting most commonly in postmenopausal women and is composed of adenocarcinomatous and sarcomatous elements and, depending on the types of these elements, can be classified as homologous or heterologous. It often has a poor prognosis.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0003792
- UMLS:C0392998
- NCIT:C9192
Additional Mondo synonyms (41)
carcinosarcoma of ovary · carcinosarcoma of the ovary · malignant mixed mesodermal Mullerian neoplasm of ovary · malignant mixed mesodermal Mullerian neoplasm of the ovary · malignant mixed mesodermal Mullerian tumor of ovary · malignant mixed mesodermal Mullerian tumor of the ovary · malignant mixed mesodermal Mullerian tumour of ovary · malignant mixed mesodermal Mullerian tumour of the ovary · malignant mixed mesodermal Müllerian neoplasm of ovary · malignant mixed mesodermal Müllerian neoplasm of the ovary · malignant mixed mesodermal Müllerian tumor of ovary · malignant mixed mesodermal Müllerian tumor of the ovary · malignant mixed mesodermal Müllerian tumour of ovary · malignant mixed mesodermal Müllerian tumour of the ovary · ovarian MMMT · ovarian carcinosarcoma · ovarian malignant mesodermal (Mullerian) mixed tumor · ovarian malignant mesodermal (Mullerian) mixed tumour · ovarian malignant mesodermal (Müllerian) mixed tumor · ovarian malignant mesodermal (Müllerian) mixed tumour · ovarian malignant mesodermal (mullerian) mixed tumor · ovarian malignant mesodermal (mullerian) mixed tumour · ovarian malignant mixed Mullerian neoplasm · ovarian malignant mixed Mullerian tumor · ovarian malignant mixed Mullerian tumour · ovarian malignant mixed Müllerian neoplasm · ovarian malignant mixed Müllerian tumor · ovarian malignant mixed Müllerian tumour · ovarian malignant mixed epithelial mesenchymal tumor · ovarian malignant mixed epithelial mesenchymal tumour · ovarian malignant mixed mesodermal (Mullerian) tumor · ovarian malignant mixed mesodermal (Mullerian) tumour · ovarian malignant mixed mesodermal (Müllerian) tumor · ovarian malignant mixed mesodermal (Müllerian) tumour · ovarian malignant mixed mesodermal Mullerian neoplasm · ovarian malignant mixed mesodermal Mullerian tumor · ovarian malignant mixed mesodermal Mullerian tumour · ovarian malignant mixed mesodermal Müllerian neoplasm · ovarian malignant mixed mesodermal Müllerian tumor · ovarian malignant mixed mesodermal Müllerian tumour · ovary carcinosarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
966 matched papers (591 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
26 matched on ClinicalTrials.gov (7 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
966
966 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
966 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
591 in the last 10 years · high confidence · 91.2th percentile (publications denominator)
Phrase hits: 966 · MeSH hits: 0
Who's working on it?
1,322
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Hollis RL6 papers · 2024
The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK. robb.hollis@ed.ac.uk.
Papers in Europe PMC - 02McNamara B6 papers · 2026
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States of America.
Papers in Europe PMC - 03Barker HE5 papers · 2026
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Papers in Europe PMC - 04Herrington CS5 papers · 2024
The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK.
Papers in Europe PMC - 05Ratner E5 papers · 2026
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States of America.
Papers in Europe PMC - 06Scott CL5 papers · 2026
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Papers in Europe PMC - 07Altwerger G4 papers · 2026
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States of America.
Papers in Europe PMC - 08Bellone S4 papers · 2025
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States of America.
Papers in Europe PMC - 09Churchman M4 papers · 2024
The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK.
Papers in Europe PMC - 10Demirkiran C4 papers · 2025
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States of America.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
26
interventional trials for this specific condition
26 interventional trials matched this specific condition name; 7 currently recruiting in our sample.
Data as of 27 July 2026
26 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 95.3th percentile).
high confidence · 95.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
26 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05902988·RECRUITING·A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Conditions: Advanced Solid Tumor · High Grade Serous Adenocarcinoma of Ovary · Squamous Non-small-cell Lung Cancer · Triple Negative Breast Cancer·Matched via name phrase
- NCT06639074·RECRUITING·Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Conditions: Advanced Fallopian Tube Carcinoma · Advanced Fallopian Tube High Grade Serous Adenocarcinoma · Advanced Ovarian Carcinoma · Advanced Ovarian Carcinosarcoma·Matched via name phrase
- NCT04919629·RECRUITING·APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Conditions: Fallopian Tube Carcinosarcoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Serous Adenocarcinoma·Matched via name phrase
- NCT05920798·RECRUITING·Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Carcinosarcoma · Primary Peritoneal Carcinosarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Fallopian Tube Clear Cell Adenocarcinoma·Matched via name phrase
- NCT05619913·RECRUITING·EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Conditions: Ovarian Carcinosarcoma · Uterine Carcinosarcoma·Matched via name phrase
- NCT03651206·RECRUITING·Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Conditions: Ovarian Carcinosarcoma · Endometrial Carcinosarcoma·Matched via name phrase
- NCT06483048·RECRUITING·MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Conditions: Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Malignant mixed Müllerian tumor of the ovary" OR "Malignant mixed Müllerian tumor of ovary" OR "MMMT of the ovary" OR "MMMT of ovary" OR "Ovarian carcinosarcoma" OR "Ovarian malignant mixed Müllerian tumor" OR "Ovarian malignant mixed epithelial mesenchymal tumor" OR "carcinosarcoma of ovary" OR "carcinosarcoma of the ovary" OR "malignant mixed mesodermal Mullerian neoplasm of ovary" OR "malignant mixed mesodermal Mullerian neoplasm of the ovary" OR "malignant mixed mesodermal Mullerian tumor of ovary" OR "malignant mixed mesodermal Mullerian tumor of the ovary" OR "malignant mixed mesodermal Mullerian tumour of ovary" OR "malignant mixed mesodermal Mullerian tumour of the ovary" OR "malignant mixed mesodermal Müllerian neoplasm of ovary" OR "malignant mixed mesodermal Müllerian neoplasm of the ovary" OR "malignant mixed mesodermal Müllerian tumor of ovary" OR "malignant mixed mesodermal Müllerian tumor of the ovary" OR "malignant mixed mesodermal Müllerian tumour of ovary" OR "malignant mixed mesodermal Müllerian tumour of the ovary" OR "ovarian MMMT" OR "ovarian malignant mesodermal (Mullerian) mixed tumor" OR "ovarian malignant mesodermal (Mullerian) mixed tumour" OR "ovarian malignant mesodermal (Müllerian) mixed tumor" OR "ovarian malignant mesodermal (Müllerian) mixed tumour" OR "ovarian malignant mixed Mullerian neoplasm" OR "ovarian malignant mixed Mullerian tumor" OR "ovarian malignant mixed Mullerian tumour" OR "ovarian malignant mixed Müllerian neoplasm" OR "ovarian malignant mixed Müllerian tumour" OR "ovarian malignant mixed epithelial mesenchymal tumour" OR "ovarian malignant mixed mesodermal (Mullerian) tumor" OR "ovarian malignant mixed mesodermal (Mullerian) tumour" OR "ovarian malignant mixed mesodermal (Müllerian) tumor" OR "ovarian malignant mixed mesodermal (Müllerian) tumour" OR "ovarian malignant mixed mesodermal Mullerian neoplasm" OR "ovarian malignant mixed mesodermal Mullerian tumor" OR "ovarian malignant mixed mesodermal Mullerian tumour" OR "ovarian malignant mixed mesodermal Müllerian neoplasm"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Malignant mixed Müllerian tumor of the ovary" OR "Malignant mixed Müllerian tumor of ovary" OR "MMMT of the ovary" OR "MMMT of ovary" OR "Ovarian carcinosarcoma" OR "Ovarian malignant mixed Müllerian tumor" OR "Ovarian malignant mixed epithelial mesenchymal tumor" OR "carcinosarcoma of ovary" OR "carcinosarcoma of the ovary" OR "malignant mixed mesodermal Mullerian neoplasm of ovary" OR "malignant mixed mesodermal Mullerian neoplasm of the ovary" OR "malignant mixed mesodermal Mullerian tumor of ovary" OR "malignant mixed mesodermal Mullerian tumor of the ovary" OR "malignant mixed mesodermal Mullerian tumour of ovary" OR "malignant mixed mesodermal Mullerian tumour of the ovary" OR "malignant mixed mesodermal Müllerian neoplasm of ovary" OR "malignant mixed mesodermal Müllerian neoplasm of the ovary" OR "malignant mixed mesodermal Müllerian tumor of ovary" OR "malignant mixed mesodermal Müllerian tumor of the ovary" OR "malignant mixed mesodermal Müllerian tumour of ovary" OR "malignant mixed mesodermal Müllerian tumour of the ovary" OR "ovarian MMMT" OR "ovarian malignant mesodermal (Mullerian) mixed tumor" OR "ovarian malignant mesodermal (Mullerian) mixed tumour" OR "ovarian malignant mesodermal (Müllerian) mixed tumor" OR "ovarian malignant mesodermal (Müllerian) mixed tumour" OR "ovarian malignant mixed Mullerian neoplasm" OR "ovarian malignant mixed Mullerian tumor" OR "ovarian malignant mixed Mullerian tumour" OR "ovarian malignant mixed Müllerian neoplasm" OR "ovarian malignant mixed Müllerian tumour" OR "ovarian malignant mixed epithelial mesenchymal tumour" OR "ovarian malignant mixed mesodermal (Mullerian) tumor" OR "ovarian malignant mixed mesodermal (Mullerian) tumour" OR "ovarian malignant mixed mesodermal (Müllerian) tumor" OR "ovarian malignant mixed mesodermal (Müllerian) tumour" OR "ovarian malignant mixed mesodermal Mullerian neoplasm" OR "ovarian malignant mixed mesodermal Mullerian tumor" OR "ovarian malignant mixed mesodermal Mullerian tumour" OR "ovarian malignant mixed mesodermal Müllerian neoplasm"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 26 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ovarian malignant mixed mesodermal Müllerian tumor; ovarian malignant mixed mesodermal Müllerian tumour; ovary carcinosarcoma
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:33:37.453Z